BRAF and neoplasm: Niemeier et al. have proposed a molecular-pathologic score based on a set of four parameters: Presence of BRAF V600E, tumor location (subcapsular, with no benign thyroid tissue between the tumor and the extrathyroid soft tissues), significant fibrosis, and intraglandular tumor spread to predict aggressive behavior (defined as lymph node metastases/tumor recurrence) [29], but with the exception of BRAF V600E that can be identified on preoperative cytology specimens, correct evaluation of the other parameters can only be performed on resected tumors.